- Home
- FMAC vs CRDL Comparison
FMAC vs CRDL Comparison
Compare FMAC & CRDL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FMAC | CRDL |
|---|---|---|
| Founded | N/A | 2017 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Blank Checks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 157.5M | 132.6M |
| IPO Year | 2026 | 2017 |
Fundamental Metrics
Financial Performance| Metric | FMAC | CRDL |
|---|---|---|
| Price | $9.97 | $0.99 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | 3.4K | ★ 338.7K |
| Earning Date | N/A | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.96 | $0.88 |
| 52 Week High | $10.02 | $1.71 |
Technical Indicators
Market Signals| Indicator | FMAC | CRDL |
|---|---|---|
| Relative Strength Index (RSI) | 46.43 | 36.09 |
| Support Level | N/A | $0.99 |
| Resistance Level | N/A | $1.10 |
| Average True Range (ATR) | 0.01 | 0.05 |
| MACD | -0.00 | 0.00 |
| Stochastic Oscillator | 28.57 | 24.00 |
Price Performance
Historical ComparisonAbout FMAC Future Money Acquisition Corporation Ordinary Shares
Future Money Acquisition Corp is a blank check company formed for the purpose of entering into a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization or similar business combination with one or more businesses or entities.
About CRDL Cardiol Therapeutics Inc.
Cardiol Therapeutics Inc is a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease. Its primary small-molecule candidate, CardiolRx, targets inflammasome pathway activation, which is involved in the development of inflammation and fibrosis in conditions such as pericarditis, myocarditis, and heart failure. The CardiolRx program includes the completed Phase II MAVERIC-Pilot study and the ongoing Phase III MAVERIC trial for the treatment of pericarditis. The ARCHER program evaluated CardiolRx in acute myocarditis through a completed Phase II study. The company is also developing CRD-38, a novel subcutaneous drug formulation for treating inflammatory heart conditions, including heart failure.